Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.
about
Sirolimus conversion efficacy for graft function improvement and histopathology in renal recipients with mild to moderate renal insufficiency.Cellular effects of everolimus and sirolimus on podocytes.TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression.Renal cortex neuronal nitric oxide synthase in response to rapamycin in kidney transplantation.Recurrent glomerulonephritis after kidney transplantation.Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effectsCalcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management.Proteinuria after kidney transplantation.Temsirolimus: a safety and efficacy review.Adverse events associated with mTOR inhibitors.mTOR inhibitors and renal allograft: Yin and Yang.A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Outcome of glomerulonephritis in live-donor renal transplant recipients: A single-centre experience.Mucocutaneous disorders in renal transplant recipients receiving sirolimus-based immunosuppressive therapy: a prospective, case-control study.Sirolimus interacts with pathways essential for podocyte integrity.Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing.Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks.Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism.microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients.Sirolimus - moving toward the mainstream in pediatric heart transplantation?Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation
P2860
Q34029931-C43BC875-5D8A-4F46-9AEF-0207B281A9DAQ35048950-D007FB3D-5E2E-4716-9504-557E9CD1FD4CQ35354812-6CECA4AD-33EB-4235-9B31-6D6D98E454CBQ36468986-877B1643-00D7-4A77-BC80-3436F6602030Q36580726-05141BD7-5E94-4110-9F3B-DC06C581BB64Q36938848-111CB16C-D965-47F2-9BF4-1B6CA323AE60Q37064446-389A16C4-427B-4EF3-9A1D-C996BB15B062Q37341185-AC8C14F3-DEA4-4E46-BF28-CDBBB3E1DD32Q38012182-91451339-A221-4E8C-9A8A-93C45736BEE7Q38031941-C1DD3913-DFBC-4A30-ACCA-9795FDEC8DC3Q38068519-C4DB9662-22BC-469F-8235-738D6A657C9EQ38209973-34AD3A27-78B4-499A-89D3-14FDFB35395CQ38286355-41EC1F5C-50B0-484B-B4EE-C8A643E11BDDQ38962103-FA131DB2-4F9A-42B1-ADC3-D1A928E7696EQ41095199-EEBA7FD5-65F5-4834-BC34-545033CBA201Q42249276-A0B0EC54-A774-421C-A8BC-535A59D6AB74Q45151652-B756D4AB-0024-422D-B37E-7A63A45741B4Q46572818-5E88A41A-0B41-44B3-9A98-78CC07BD5D56Q46646002-2345927A-D917-4043-9716-1F60AD77837AQ46856408-A591E655-D91B-44ED-8C55-36E6AFB29AE5Q46898800-BFA6513C-A4DB-4E4E-98A5-F8A1BB9BE88FQ46903645-275CED86-60EE-40F2-8B2A-06373DDEFE15Q49353844-5EE109D5-5565-4565-A68F-3A1FDB816D0FQ51189916-563E5FB3-1FFE-4B49-AC76-147E0C2D197FQ54533300-FAD8BD4F-3392-4F11-93F1-32F99AD601F1Q57151742-43FB8AA9-32EB-47B8-9365-DB583E83E679
P2860
Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.
@en
Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.
@nl
type
label
Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.
@en
Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.
@nl
prefLabel
Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.
@en
Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.
@nl
P1476
Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.
@en
P2093
P304
P356
10.1016/S0041-1345(03)00244-6
P407
P433
P577
2003-05-01T00:00:00Z